Drug Profile
CM 24
Alternative Names: CM-24; MK 6018Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator cCAM Biotherapeutics
- Developer Bristol-Myers Squibb; cCAM Biotherapeutics; Purple Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD66 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adenocarcinoma
- Phase I/II Pancreatic cancer; Solid tumours
Most Recent Events
- 14 Dec 2023 Purple Biotech completes enrolment in its phase II trial for Adenocarcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Israel and Spain
- 13 Oct 2023 Pharmacodynamics data from a phase I trial in Aadenocarcinoma released by Purple Biotech
- 11 Jul 2023 Adverse events and efficacy data from a phase I/II trial in Pancreatic cancer released by Purple Biotech